CD8A and neoplasm: Such variations may result in quantitative differences in the proteasome cleavage products, which in turn can strongly affect cell surface presentation of MHC-class I-bound virus- or tumor-specific antigenic peptides and in consequence also the efficacy of a peptide-specific CD8+ T cell response9, 10.